Thryv Therapeutics Inc., a clinical-stage biotechnology company pioneering novel therapies for cardiovascular diseases, is ...

Leerink upgraded Doximity (DOCS) to Outperform from Market Perform with a price target of $90, up from $60. While “admittedly late on this,” ...

Equities researchers at Leerink Partnrs boosted their Q2 2025 earnings estimates for shares of Twist Bioscience in a research ...

An investment banker who left Goldman Sachs & Co. for Leerink Partners LLC advanced part of her lawsuit saying she was denied promised bonuses and deferred grant awards worth millions of dollars.

What has Wall Street been buzzing about this week? Here are the top 5 Buy calls and the top 5 Sell calls made by Wall Street’s best analysts ...

Chair and CEO of Insmed Inc. (NASDAQ:INSM), recently executed a significant stock transaction amid the company's impressive 178% stock surge over the past year. According to a recent SEC filing, Lewis ...

Fintel reports that on February 6, 2025, Leerink Partners downgraded their outlook for Hologic (NasdaqGS:HOLX) from Outperform to Market Perform. Analyst Price Forecast Suggests 20.21% Upside As of ...

Stock analysts at Leerink Partnrs raised their FY2026 earnings per share estimates for shares of Amedisys in a research ...

The two biotechs, which have lost most of their share value following lucrative IPOs, are combining in a deal that leaves the ...

The company built a digital platform for medical professionals that helps carry out telehealth appointments with patients, ...

Q4 2024. Management View. CEO Mark Tarr emphasized strong financial performance in Q4 2024, with revenue increasing ...